CIK 0001799788 · Non-accelerated filer<br>Smaller reporting company
Greenwich LifeSciences, Inc.
Sign in to watch- Ticker
- GLSI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205473709
- Phone
- 203-434-3290
- Business address
- 3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
- DEFA14A Proxy Proxy Materials
- ARS Other Annual Report to Security Holders
- DEF 14A Proxy Proxy Statement
- 10-Q Report Quarterly Report
- 4 Open-market buy CEO and CFO bought 2,200 shares at an average $13.43 ($29,555)
- 4 Open-market buy CEO and CFO bought 1,500 shares at $13.62 ($20,430)
- 4 Open-market buy CEO and CFO bought 3,600 shares at an average $13.06 ($47,018)
- 10-Q Report Quarterly Report
- 10-K Report Annual Report
- NT 10-K Other NT 10-K
- 4 Open-market buy CEO and CFO bought 1,800 shares at $29.83 ($53,694)
- 4 Open-market buy CEO and CFO bought 2,900 shares at $27.54 ($79,866)
- 4 Open-market buy CEO and CFO bought 4,300 shares at $21.36 ($91,848)
- 4 Open-market buy CEO and CFO bought 2,900 shares at $21.73 ($63,017)
- 4 Open-market buy CEO and CFO bought 4,100 shares at $12.62 ($51,742)
- 8-K Event Shareholder vote results
- 4 Open-market buy CEO and CFO bought 4,600 shares at $8.37 ($38,502)
- 4 Derivatives Options or other derivatives
- 10-Q Report Quarterly Report
- 4 Open-market buy CEO and CFO bought 10,600 shares at $8.43 ($89,358)
Page 1 of 14 · 279 filings